Exhaled Breath Condensate in Allogeneic Stem Cell Recipients and the Value in Follow-up

Exhaled Breath Condensate in Allogeneic Stem Cell Recipients and Value in Follow-up

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02318316

Enrollment

Registered

2014-12-17

Start date

2014-12-31

Completion date

2016-04-30

Last updated

2014-12-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Exhaled Breath Condensate

Keywords

Exhaled breath condensate, allogeneic stem cell transplantation, pulmonary complications

Brief summary

The most effective treatment of hematologic malignancies and some benign hematological diseases is allogeneic stem cell transplantation therapy. Pulmonary complications can occur after allogeneic stem cell transplantation. And these complications effect mortality and morbidity in these patients. In this study we want to investigate the use of exhaled breath condensate (EBC) collection which is a simple and completely noninvasive method. By this way we hope to detect pulmonary complications early. EBC, has been implicated in the pathophysiology of inflammatory airway diseases such as cystic fibrosis, asthma, chronic obstructive pulmonary disease (COPD) and bronchiectasis. EBC, has not been investigated before in patients who underwent stem cell transplantation.

Interventions

OTHERExhaled breath condensate

Breath condensate samples will be collected with a commercially available condenser (EcoScreen®, Erich Jaeger, Germany). Subjects will breathe through a mouthpiece and a two-way non-rebreathing value in which inspiratory and expiratory air were separated, and saliva was trapped. They will be asked to breathe at a normal frequency and tidal volume for 15 minutes while wearing nose clips, allowing collection of 1.5-2.5 mL of condensate. After collecting this, pH will be measured and the waste collection will be stored at -80 degrees. Then 8 isoprostane and nitrotyrosine will be measured collectively

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

* hematologic malignancies or benign hematological diseases that allogeneic stem cell transplantation performed

Exclusion criteria

* allogeneic stem cell transplantation patients with Asthma or COPD

Design outcomes

Primary

Measure	Time frame
The pH level of exhaled breath condansate	2 years

Secondary

Measure	Time frame
The nitrotyrosine and 8-isoprostane levels of exhaled breath condansate	2 years

Contacts

Primary ContactNilgün Yilmaz Demirci, MD

nilgundemirci@gazi.edu.tr009031224143

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026